Marco Tucci

Bari, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 13, 2026

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2026

Tissue and circulating biomarkers in advanced melanoma patients receiving dabrafenib and trametinib.

Tissue and circulating biomarkers in advanced melanoma patients receiving dabrafenib and trametinib.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 26, 2026

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: November 23, 2025

High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors.

High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors.

Journal: Journal of translational medicine

Published: October 02, 2025

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 08, 2025

Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events.

Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events.

Journal: Biomolecules

Published: February 17, 2025

Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis.

Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis.

Journal: Cancers

Published: October 09, 2024

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.

Journal: NEJM evidence

Published: September 24, 2024

Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genes.

Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genes.

Journal: Biomarker research

Published: January 12, 2024

Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.

Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 02, 2023

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 13, 2023

Showing 1-12 of 100

Last Updated: 09/26/2026